2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH DENA BATTLE
Patient Perspectives on Cytoreductive Nephrectomy after the CARMENA Trial

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH OLIVER SARTOR
Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer

VIEW ALL PCF VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL ASCO GU 2019 VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH JAMES GULLEY
Immunotherapy Across Genitourinary Malignancies

VIEW ALL ASCO GU 2019 VIDEOS

Featured Videos

GU Cancers Symposium 2014 - Intratumoral heterogeneity and branched evolution: Implications and future directions - Session Highlights

SAN FRANCISCO, CA USA (UroToday.com) - Dr. James Larkin presented data which had generated much discussion prior to the ASCO Cancers Symposium.

For decades, intratumoral heterogeneity has been demonstrated, but its significance has not really been investigated. His group set out to investigate whether driver mutation x at time point y actually predicted patient outcome or drug sensitivity. They performed exome sequencing to identify ubiquitous, shared primary, shared metastatic and “private” mutations from several regions within the primary tumor and from several resected metastatic sites. gucancerssympalt thumbCuriously, they identified different mutations in SETD2, a recently described clear cell renal cell carcinoma, at different metastatic sites. Using a bioinformatics approach, they were able to show that the metastatic clones evolved in parallel, but separately, from the primary. These findings were extended to 10 patients now and will be available soon.

Much like Dr. Levi Garraway’s findings yesterday regarding the evolution of the prostate cancer genome, Dr Larkin’s findings have profound implications for therapy resistance. He went on to opine that evolving mutations as a result of selective pressure will not be overcome by that combination therapy, but rather that combinations will just delay the emergence of resistant clones. Further, he suggested that immunotherapy might be a better approach because it does not result in a fixed selective pressure like targeted therapy does, but rather the immune system can also evolve to match intratumoral heterogeneity.

Highlights of a presentation by James Larkin, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

The Royal Marsden, London England

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe